TAVŞAN ATG+ FLUDARABİN+ SİKLOFOSFAMİD PROTOKOLÜ

Kaynaklar:

1-Gallo, S., A. E. Woolfrey, L. M. Burroughs, et al. 2016. "Marrow grafts from HLA-identical siblings for severe aplastic anemia: does limiting the number of transplanted marrow cells reduce the risk of chronic GvHD?" Bone Marrow Transplant 51(12):1573-1578.

2-Michonneau, D., G. Socie. 2019. "The EBMT Handbook: GVHD Prophylaxis (Immunosuppression)". Springer International Publishing. Pages 177-182

3-Bhurani, D., M. Schifter and I. Kerridge. 2008. "Folinic acid administration following MTX as prophylaxis for GVHD in allogeneic HSCT centres in Australia and New Zealand." Bone Marrow Transplant 42(8):547-550.

3- Bressler RB and Huston DP 1985. "Water intoxication following moderate-dose intravenous cyclophosphamide." Arch Intern Med Mar;145(3):548-9.

3-Kang, H. J., K. T. Hong, J. W. Lee, et al. 2016. "Improved Outcome of a Reduced Toxicity-Fludarabine, Cyclophosphamide, plus Antithymocyte Globulin Conditioning Regimen for Unrelated Donor Transplantation in Severe Aplastic Anemia: Comparison of 2 Multicenter Prospective Studies." Biol Blood Marrow Transplant 22(8):1455-1459.

4-Bacigalupo, A., F. Locatelli, E. Lanino, et al. 2005. "Fludarabine, cyclophosphamide and anti-thymocyte globulin for alternative donor transplants in acquired severe aplastic anemia: a report from the EBMT-SAA Working Party." Bone Marrow Transplant 36(11):947-950.

5-Kako, S., Y. Kanda, M. Onizuka, et al. 2020. "Allogeneic hematopoietic stem cell transplantation for aplastic anemia with pre-transplant conditioning using fludarabine, reduced-dose cyclophosphamide, and low-dose thymoglobulin: A KSGCT prospective study." Am J Hematol 95(3):251-257.